GRL-079

CAS No.

GRL-079 ( GRL079 )

Catalog No. M17094 CAS No.

GRL-079 is a novel potent, nonpeptidic HIV-1 protease inhibitor with 2.5-30 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GRL-079
  • Note
    Research use only, not for human use.
  • Brief Description
    GRL-079 is a novel potent, nonpeptidic HIV-1 protease inhibitor with 2.5-30 nM.
  • Description
    GRL-079 is a novel potent, nonpeptidic HIV-1 protease inhibitor with 2.5-30 nM against wild-type HIV-1NL4-3, 0.3-6.7 nM against HIV-2EHO, and 0.9-90 nM against laboratory-selected-PI-resistant HIV-1 and clinical HIV-1 variants resistant to multiple FDA-approved PIs (HIVMDR).
  • Synonyms
    GRL079
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    --
  • Formula Weight
    703.91
  • Molecular Formula
    C34H49N5O7S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    (3R,3aS,4S,7aS)-3-(ethylamino)hexahydro-4H-furo[2,3-b]pyran-4-yl ((2S,3R)-4-((2-(cyclopropylamino)-N-isobutylbenzo[d]thiazole)-6-sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Delino NS, et al. Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02060-17.
molnova catalog
related products
  • Peptide T TFA

    Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.

  • ALW-II-41-27

    ALW-II-41-27, an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.

  • KNI-1657

    KNI-1657 (KNI1657) is a highly potent HIV-1 protease inhibitor (97% inhibition at 1 nM) with high sensitivity against lopinavir/ritonavir- or darunavir-resistant strains.